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Abstract
Monocarboxylate transporters MCT1-MCT4 require basigin (CD147) or embigin (gp70), ancillary proteins with a
glutamate residue in their single transmembrane (TM) domain, for plasma membrane (PM) expression and activity. Here
we use site-directed mutagenesis and expression in COS cells or Xenopus oocytes to investigate whether this glutamate
(Glu218 in basigin) may charge-pair with a positively charged TM-residue of MCT1. Such residues were predicted using a
new molecular model of MCT1 based upon the published structure of the E. coli glycerol-3-phosphate transporter. No
evidence was obtained for Arg306 (TM 8) of MCT1 and Glu218 of basigin forming a charge-pair; indeed E218Q-basigin
could replace WT-basigin, although E218R-basigin was inactive. No PM expression of R306E-MCT1 or D302R-MCT1
was observed but D302R/R306D-MCT1 reached the PM, as did R306K-MCT1. However, both were catalytically inactive
suggesting that Arg306 and Asp302 form a charge-pair in either orientation, but their precise geometry is essential for
catalytic activity. Mutation of Arg86 to Glu or Gln within TM3 of MCT1 had no effect on plasma membrane expression or
activity of MCT1. However, unlike WT-MCT1, these mutants enabled expression of E218R-basigin at the plasma
membrane of COS cells. We propose that TM3 of MCT1 lies alongside the TM of basigin with Arg86 adjacent to Glu218 of
basigin. Only when both these residues are positively charged (E218R-basigin with WT-MCT1) is this interaction
prevented; all other residue pairings at these positions may be accommodated by charge-pairing or stabilization of unionized
residues through hydrogen bonding or local distortion of the helical structure.
Keywords: Lactate transport, MCT1, CD147, basigin, monocarboxylate transport, ﬂuorescence resonance energy transfer,
protein/protein interaction, site-directed mutagenesis, Xenopus oocytes
Abbreviations: BCECF, 2?-7?-bis(carboxyethyl)-5-6-carboxy-ﬂuorescein; basigin-c-YFP, basigin tagged on the
C-terminus with YFP; basigin-n-YFP, basigin tagged on the N-terminus with YFP; CFP, cyan variant of green
ﬂuorescent protein; MCT, monocarboxylate transporter; MCT1-c-CFP, MCT1 tagged on the C-terminus with
CFP; SDM, site-directed mutagenesis; TM, transmembrane domain; WT, wild-type; YFP, yellow variant of green
ﬂuorescent protein.
Introduction
The rapid proton-linked transport of monocarboxy-
lates such as lactate and pyruvate across the plasma
membrane plays a critical role in the metabolism
and pH regulation of most cells (Poole & Halestrap
1993). Monocarboxylate transport is mediated by
a family of monocarboxylate transporters (MCTs)
of which there are now known to be 14 mem-
bers, although only for members 1 4 has lactate
and pyruvate transport been demonstrated directly
(Halestrap & Price 1999, Halestrap & Meredith
2004). The MCTs are 12 transmembrane domain
(TM) proteins with most sequence variation found
in the long intracellular loop between TMs 6 and 7,
the short N-terminal domain and the longer intra-
cellular C-terminal domain (Halestrap & Price
1999). In order to be translocated correctly to the
plasma membrane, MCTs 1 4 require the ancillary
protein basigin (also known as CD147) or its
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Halestrap 1997, Kirk et al. 2000, Philp et al. 2003).
These two proteins are closely related and comprise
a single TM containing a conserved glutamate
residue, a short intracellular C-terminal domain
and a larger extracellular N-terminal domain con-
taining 2 or 3 immunoglobulin folds (Muramatsu &
Miyauchi 2003). Co-immunoprecipitation studies
have shown that basigin, rather than embigin,
normally associates with both MCT1 and MCT4
in the plasma membrane of most tissues. However,
embigin can fulfil this role when no basigin is
expressed, as is the case in erythrocytes of some
species such as the rat, and is essential for MCT2
expression (Kirk et al. 2000; Wilson et al. 2005).
Continued association between MCT1 or MCT4
and its ancillary protein is required for transport
activity, and disruption of this interaction by cova-
lent modification of basigin with the organomercur-
ial reagent p-chloromercuribenzene sulphonate
(pCMBS), inhibits transport (Wilson et al. 2005).
We have also used fluorescence resonance energy
transfer (FRET) between MCTs tagged with cyan-
fluorescent protein (CFP) and basigin or embigin
tagged with yellow-fluorescent protein (YFP) to
confirm the continuing interaction of proteins within
the plasma membrane (Wilson et al. 2002).
Using chimeras of CD2 and basigin we have
shown that the extracellular domain of the ancillary
protein is not involved in its interaction with MCTs
(Kirk et al. 2000). Thus an interaction between the
TM of basigin or embigin and TM (s) of the MCTs
seems likely. This would be consistent with the
presence of a glutamate in the TM of basigin, since
this is unusual in a single-pass (monotopic) protein
(Green 1991), and may reflect the formation of a
charge-pair with a positive residue in a TM of the
MCT. Our earlier sequence-based structural predic-
tions (Halestrap & Price 1999) combined with the
site-directed mutagenesis studies of Stefan Bro ¨er’s
laboratory (Rahman et al. 1999, Galic et al. 2003)
implicate Arg306 in TM 8 (numbering based on rat
MCT1) as a potential candidate for such a charge-
pair and this provided the initial focus for the stud-
ies reported here. However, structural predictions
(Wilson et al. 2005) based around the published
crystal structures of two members of the major
facilitator superfamily, the E. coli glycerol-3-phos-
phate transporter (GlpT) and lactose permease
(LacY) (Huang et al. 2003, Abramson et al. 2003)
suggest that there may be other positively-charged
residues in other TM domains of MCT1 capable of
forming charge-pairs with the TM glutamate of
basigin. These are Arg86, Arg196 and His337. Prior
to the ability to model MCT1 upon the E. coli
glycerol-3-phosphate transporter (GlpT) and lactose
permease (LacY) Bro ¨er’s group had mutated poten-
tial TM charged resides to investigate their impor-
tance in MCT1 translocation and activity (Rahman
et al. 1999, Galic et al. 2003). These studies showed
that mutation of His337 to glutamine was without
effect on MCT1 targeting to the plasma membrane
and its activity (Rahman et al. 1999). They also
showed that the same was true for Lys137,L y s 141,
Lys142, but that R143Q-MCT1, whilst correctly
targeted, was inactive. These data suggest that
the positive charge of Arg143 may be important
for activity but not plasma membrane expression
(Rahman et al. 1999, Galic et al. 2003). This
conclusion was strengthened by the observation
that the R143H mutant was active (Rahman et al.
1999). In this paper we investigate whether Arg86
and Arg196 may play a critical role in MCT1 activity
or interaction with basigin and also provide a more
rigorous structural model for MCT1 with which to
interpret our data.
Materials and methods
All reagents were obtained from Sigma (Poole, UK)
unless otherwise stated. Polyclonal antibodies
against the C-terminal 16 amino acids of rat
MCT1 and human basigin were raised in rabbits
as described previously (Poole et al. 1996, Wilson
et al. 2005). The mouse mAb RET.PE-2 recognizing
rat basigin (Finnemann et al. 1997) was a generous
gift of Dr Neil Barclay (University of Oxford).
Secondary antibodies for western blotting were
from Amersham Biosciences (anti-rabbit) and Sigma
(anti-chicken). An antisense nucleotide (TTCTCA-
TAAATAAAGATTATTGTG) against Xenopus lae-
vis basigin was chemically synthesized (Wilson et al.
2005).
Cloning of cDNA constructs
The coding regions of human basigin and rat MCT1
were sub-cloned into the EcoRI site of the pCI-neo
mammalian expression vector (Promega) and the
Xenopus oocyte vector pGHj as described elsewhere
(Manning Fox et al. 2000, Wilson et al. 2005).
The pCI-neo constructs required to express rat
MCT1 and human basigin tagged on the N- and
C-termini with CFP or YFP were produced as
described previously (Wilson et al. 2002, Wilson
et al. 2005).
Site-directed mutagenesis
Site-directed mutagenesis (SDM) of MCT1 and
basigin within the relevant vector was performed
using the QuikChange kit (Stratagene, UK) and the
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sequencing. Primers containing the desired muta-
tion were designed to be between 25 and 45 bases in
length with a melting point greater that 788C and are
shown in Supplementary online data Table I. Typi-
cally, for mutant MCT1, thermocycling was per-
formed using the following parameters: 30 sec at
958C, 30 sec at 558C and a 4.8 min extension time at
688C. PCR conditions for creating mutant basigin
were similar but with an extension time of 4 min.
Expression of basigin and MCT1 in Xenopus oocytes
Preparation of oocytes from mature adult female
Xenopus laevis was performed by a modified techni-
que that was found to improve stability following
microinjection. The ovarian lobes were removed,
transferred to a Petri dish containing sterile-filtered
zero Ca
2  ND96 solution (93.5 mM NaCl, 2 mM
KCl, 2.96 mM MgCl2 and 5 mM HEPES pH 7.4)
and cut into 0.5 cm
2 pieces. Cut lobes (5 g) were
then placed into a 50 ml plastic tube and washed for
6  /15 min in 20 ml of zero calcium ND96 solution
on a rotating wheel (approx. 5 revs/min) prior to
digestion in 20 ml sterile-filtered zero calcium ND96
containing 8 mg/ml Type I collagenase for 30 min on
a rotating wheel. The digested lobes were washed
with 3  /20 ml zero calcium ND96, and then subject
to another 30 min collagenase digestion before
washing with 4  /40 ml zero calcium ND96. The
resulting oocytes were placed into a fresh 50 ml
tube containing 40 ml of normal calcium (1.8 mM)
ND96 solution and washed a further four times.
Finally, oocytes were transferred to a Petri dish
containing sterile filtered OR3 medium (200 ml
Leibovitz L-15 medium, 136.6 ml milli Q water
and 3.4 ml 100  /penicillin/streptomycin) and incu-
bated at 188C overnight prior to injection. cRNA
was prepared by in vitro transcription from the ap-
propriate linearized pGHJ plasmid (mMessage
mMachine, Ambion, Texas, USA). Oocytes were
injected with 10 25 ng of the relevant cRNA (MCT,
embigin or basigin) and, where required, 200 ng of
antisense cDNA against Xenopus basigin (see Wilson
et al. 2005). Controls received the equivalent volume
(14 nl) of water. Oocytes were then cultured in OR3
medium for at least 48 72 hrs with fresh medium
each day.
Measurement of L-lactate transport into Xenopus oocytes
Measurements were either made by following the
change in intracellular pH using the ratiometric
pH-sensitive fluorescent dye 2?-7?-bis(carbox-
yethyl)-5-6-carboxy-fluorescein (BCECF) as descri-
bed previously (Manning Fox et al. 2000, Wilson
et al. 2005) or by determining the rate of uptake
of L-[
14C]-lactate. For the latter protocol, 4 6
oocytes were placed in 1.5ml microcentrifuge tubes
containing 100 ml uptake buffer (75 mM NaCl,
2 mM KCl, 0.82 mM MgCl2, 1 mM CaCl2,
20 mM Tris/HEPES, pH 7.4) and allowed to
equilibrate for 1 min. The uptake solution was
then removed by aspiration and replaced with
100 ml uptake buffer containing L-[
14C]-lactate
(0.5 mM, 7.4 MBq/ ml). Following incubation for
the required time at room temperature (22 258C),
the oocytes were rapidly washed five times with ice-
cold uptake buffer. After the final wash each egg
was transferred into a scintillation vial and homo-
genized in 100 ml 2% (w/v) SDS by vigorous
pipetting prior to addition of 10 ml of scintillation
fluid (Emulsifier-Safe, Perkin Elmer) and assay of
[
14C] by scintillation counting.
Detection of MCT1and basigin expression by western
blotting and immunofluorescence microscopy
A crude oocyte membrane preparation was used for
detection of MCT1 and basigin expression by SDS-
PAGE and western blotting as described previously
(Friesema et al. 2003). For immunofluorescence,
each oocyte was embedded in a 1 cm
3 block of
chicken liver with O.C.Tembedding compound and
snap frozen using liquid N2 cooled pentane. These
blocks were then frozen to chucks with CRYO-M-
BED embedding compound using cryospray at
approximately   /528C, and sections were cut in a
cryostat at a thickness of 5 mm using a steel blade.
Sections were transferred onto multispot microscope
slides and fixed by placing in a chamber containing
ice-cold acetone for 15 mins. Immunofluorescence
microscopy was performed using the appropriate
antibodies as detailed elsewhere (Friesema et al.
2003).
Expression of MCT1 and basigin constructs in COS-7
cells for immunofluorescence microscopy, live cell imaging
and FRET
COS-7 cells were transfected with the required
constructs using Fugene 6 and incubated in a CO2
incubator for 48 h prior to measurement of protein
expression. This was performed by immunofluores-
cence in fixed cells (Wilson et al. 1998) or directly
in live cells expressing CFP- and YFP- tagged
proteins where fluorescence resonance energy trans-
fer (FRET) was also determined using a Leica
confocal imaging spectrophotometer system (TCS-
SP2) attached to a Leica DMIRBE inverted epi-
fluorescence microscope (Wilson et al. 2002, Wilson
et al. 2005). Quantification of FRETwas performed
488 C. Manoharan et al.by calculation of the ratio of the fluorescence
intensity emission signal at 480 nm to that at 530
nm when excited at the CFP excitation wavelength
(430 nm). In all cases a 63  /1.32 Na oil immersion
objective was employed. When required, crude
plasma membrane fractions were prepared from
cultured cells in the presence of protease inhibitors
as described previously (Wilson et al. 2005).
Modelling the structure of MCT1
MCT sequences are only 10 15% identical to the
two members of the superfamily whose crystal
structures have been published, E. Coli glycerol-3-
phosphate transporter (GlpT-1PW4, 3.3 A ˚; Huang
et al. 2003) and lactose permease (LacY-1PV6, 3.5
A ˚; Abramson et al. 2003). Such low sequence
identity (within the ‘random zone’) would typically
preclude homology modelling. However, the MCT
sequences contain an extra layer of information in
the form of Trans-Membrane (TM) sequence sig-
nals that allow coarse registration of the target onto
the template. These TM signals also afford sufficient
amino-acid similarities (rather than identities) for
alignment programs to find reasonably gap-free
alignments of the MCT family with the template
sequences. Initially, we used the alignments provided
by Cn3D (http://www.ncbi.nlm.nih.gov/Structure/
CN3D/cn3dtut.shtml) to produce a provisional
model of the MCT1, MCT2 and MCT4 structures
and encouragingly, the models built on the two
templates superimposed reasonably well (Wilson
et al. 2005). In this study we have refined this model
by using other alignment software such as ClustalW,
matching the TM sequence signals predicted by
TMHMM to TM-helices in the templates, and
finally by using molecular graphics (InsightII, Ac-
celrys) to modify the registration of the target
sequence on helices in the template structure to
best accommodate residue sidechains. The model-
ling process yielded the final sequence alignment
shown in Figure 1. All loop insertions and deletions
were modelled apart from the large loop between the
N-terminal and C-terminal domains of the protein.
Any remaining sidechain clashes were relieved by
appropriate rotamer choices made by inspection.
Further refinement of the model was peformed by
energy minimisation (Discover 2.95, Accelrys) while
restraining the backbone to the corresponding tem-
plate backbone. While analysis of the model showed
it to possess acceptable stereochemical properties
(Procheck) we still consider the model obtained here
to be of ‘intermediate’ quality. Although consider-
able uncertainty remains over the precise registering
of residues along the TM-helices, as might be
expected from the low sequence identities, the
model exhibits several features consistent with
known experimental data from site-directed muta-
genesis as will be described more fully in the
Discussion. Thus it is likely to be a good predictor
of the location of charged residues in TM regions.
Results
The glutamate in the TM of basigin is not critical for
activity
We have previously proposed that Glu218 in the TM
of basigin might form a charge-pair with a positively
charged residue in a TM of its partner MCT (Kirk
et al. 2000, Halestrap & Meredith 2004). We first
tested this possibility by mutating this glutamate to
the uncharged glutamine or to the positively charged
arginine and determining the ability of the mu-
tants to support expression of active MCT1 in Xeno-
pus oocytes. These cells do not express endogenous
MCT activity, but they do possess an endogenous
basigin that can support the expression of exoge-
nous MCT1 from injected cRNA. This expression
can be largely prevented by using antisense cRNA to
knock down the endogenous basigin (Wilson et al.
2005). The western blots of Fig. 2A confirm that
MCT1 expression was greatly reduced by the
basigin antisense cRNA and that this was associated
with a major reduction of lactate transport into the
oocytes (Figure 2B). As predicted, when cRNA for
rat WT-basigin was also injected, transport activity
was restored (Figure 2B) and this was associated
with MCT1 and basigin expression in the membrane
fraction (Figure 2A). Transport activity was also
restored when cRNA for the E218Q mutant of
basigin was co-injected but E218R-basigin did not
restore activity the small effect being statistically
insignificant (Figure 2B). The large variation in rates
of lactate transport seen when oocytes were injected
with rat basigin cRNA together with antisense cRNA
against Xenopus basigin (reflected in the large SEM),
is thought to reflect incomplete endogenous basigin
knockdown. Unfortunately we do not have a suitable
antibody to confirm this.
In Figure 3 we confirm these data in COS cells
transfected with cDNAs encoding basigin tagged on
the C-terminus with YFP (basigin-c-YFP) and
MCT1 tagged on the C-terminus with CFP
(MCT1-c-CFP). The presence of both proteins at
the membrane was confirmed with live cell confocal
imaging. Once again the E218Q basigin mutant was
correctly targeted to the plasma membrane with
MCT1 whilst the E218R mutant was largely re-
tained in the perinuclear region. FRET confirmed
that the E218Q-basigin-c-YFP was interacting
with MCT1-c-CFP at the plasma membrane,
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r-MCT1    1 MPPAIGGPVG YTPPDGGWGW AVVVGAFISI GFSYAFPKSI TVFFKEIEII FSATTSEVSW ISSIMLAVMY AGGPISSILV 80
1PW4_A   12 ARLPAAEIDP TYRRLRWQIF LGIFFGYAAY YLVRKNFALA MPYLVEQGFS RGDLGFALSG ISIAYGFSKF IMGSVSD-RS 90
r-MCT1   81 NKYGSRPVMI AGGCLSGCGL IAASF---CN TVQELYFCIG VIGGLGLAFN LNPALTMIGK YFYKKRPLAN GLAMAGSPVF 157 
1PW4_A   91 NPRVFLPAGL ILAAAVMLFM GFVPWATSSI AVMFVLLFLC GWFQGMGWPP CGRTMVHWWS QKERGGIVSV WNCAHNVGGG 170 
r-MCT1  158 LSTLAPLNQA FFGIFG--WR GSFLILG-GL LLNCCVAGSL MRPIGPQQGK VEKLKSkesl qeagksdant dliggspkge 234 
1PW4_A  171 IPPLLFLLGM AWFNDWHAAL YMPAFCAILV ALFAFAMMRD TPQSCGLPPI EEYKND---- --------yp ddynekaeqe 238 
r-MCT1  235 klsvfqTVNK FLDLSLFTHR GFLLYLSGNV VMFFGLFTPL VFLSNYGKSK HF-SSEKSAF LLSILAFVDM VARPSMGLAA 313 
1PW4_A  239 l-----TAKQ IFMQYVLPNK LLWYIAIANV FVYLLRYGIL DWSPTYLKEV KHFALDKSSW AYFLYEYAGI PGTLLCGWMS 313 
r-MCT1  314 N—-TRWIRPR VQYFFAASVV ANGVCHLLAP LSTTYVGFCI YAGVFGFAFG WLSSVLFETL MDLVGPQRFS SAVGLVTIVE 391 
1PW4_A  314 DKVFRGNRGA TGVFFMTLVT IATIVYWMNP AGNPTVDMIC MIVIGFLIYG PVMLIGLHAL ELA-PKKAAG TAAGFTGLFG 392 
r-MCT1  392 CCP-VLLGPP LLGRLNDMYG DYKYTYWACG VILIIAGLYL FIGMGINYRL VAKEQKAEE 449 
1PW4_A  393 YLGGSVAASA IVGYTVDFFG WDGGFMVMIG GSILAVILLI VVMIGEKRRH EQLLQELVP 451
Figure 1. Homology model of rat MCT1 based on the E. coli glycerol 3-phosphate transporter (1PW4) template. The ribbon is coloured
from red to purple along the sequence according to the horizontal bar (N to C). The numbered residues refer to those discussed in the text.
Acidic residues (Asp, Glu) are represented by red spheres at the C-alpha position, basic residues (Arg, Lys) by blue spheres, histidine by
pink spheres and aromatic residues frequently found at the phospholipid interface (Tyr, Trp) in yellow. Phe306, that is known to be in the
substrate-binding pocket, is shown in brown. The black vertical bar measures 30 A ˚ and marks the ‘best guess’ position of the lipid bilayer.
The sequence alignment of rat MCT1 with the E. coli glycerol 3-phosphate transporter used to generate the model is shown beneath the
model. Lower case letters refer to residues not built in the model and residues not present in the 1PW4 crystal structure respectively.
Sequence in red refers to TM-helices in the template and predicted by TMHMM in the target sequence.
490 C. Manoharan et al.the ratio of the fluorescence intensity emission signal
at 480nm to that at 530nm when excited at the CFP
excitation wavelength (430nm) being 0.8339 /0.047
(mean9 /SEM, n  /17) compared with a value of
0.7999 /0.037 (n  /23) for the WT-basigin-c-YFP in
the same experiment. By contrast, for the E218R-
basigin-c-YFP co-expressed with MCT1-c-CFP the
ratio was 1.0349 /0.032 (n  /12) that is similar to the
value of 1.1189 /0.015 (n  /25) obtained using
basigin-n-YFP co-expressed with MCT1-c-CFP. In
the latter case, FRET is not possible because the
YFP and CFP are on opposite sides of the plasma
membrane and the ratio is similar to that for CFP
expressed alone (Wilson et al. 2002, Wilson et al.
2005). Taken together, these data imply that the
negative charge of basigin E218 is not critical for its
ability to correctly chaperone MCT1 to the plasma
membrane, although replacement with a positive
charge is not tolerated.
Arg306 is essential for MCT1 activity and forms a
charge-pair with Asp302 in TM 8 of MCT1 but not
Glu218 of basigin
The cRNA encoding both WT- and R306E-MCT1
was microinjected into Xenopus oocytes in the
presence and absence of cRNA for either WT- or
E218R-basigin. Western blotting of a membrane
fraction (Figure 4B) and immunofluorescence mi-
croscopy of oocyte sections (Figure 4A) demon-
strated that only WT-MCT1 and WT-basigin, but
neither R306E-MCT1 nor E218R-basigin, was ex-
pressed at the plasma membrane of the oocytes. This
was true whatever combination of proteins was ex-
pressed, demonstrating that a charge swap was not
tolerated. The same result was obtained in COS cells
transfected with the CFP- and YFP-tagged MCT1
and basigin mutants (Figure 3). In a separate series
MCT1 43kDa
0 1 1A 1AB
0 1AB
Basigin 45 kDa
R
a
t
e
 
o
f
 
 
l
a
c
t
a
t
e
 
u
p
t
a
k
e
 
(
∆
F
 
r
a
t
i
o
 
p
e
r
 
m
i
n
)
0
0.03
0.06
0.09
0.12
0.15
0.18
AS AS + 
WT
AS + 
E218Q
AS + 
E218R
A
B
Figure 2. The E218Q mutant of basigin, but not the E218R
mutant, supports lactate transport by MCT1 in Xenopus oocytes.
In panel A, oocytes were injected with water (0), or cRNA for
MCT1 (1) in the absence or presence (A) of antisense cRNA
against Xenopus basigin and cRNA for rat basigin (B). Western
blots are shown for the crude plasma membrane fraction using
both MCT1 and basigin antibodies. In panel B rates of L-lactate
(30 mM) transport into oocytes measured using BCECF ﬂuores-
cence are shown as means9 /SEM of 5 8 separate oocytes. Where
indicated, antisense (AS) against Xenopus basigin as well as the
cRNA for WT-, E218Q- or E218R-basigin was co-injected with
the MCT1 cRNA.
MCT1-c-CFP mutant used
40 µ µm
WT WT WT R306E R306E
WT E218Q WT E218R E218R
Basigin-c-YFP mutant used
Figure 3. The E218Q mutant of basigin, but not the E218R mutant, is correctly targeted to the plasma membrane of COS cells. COS cells
were co-transfected with MCT1-c-CFP and basigin-c-YFP constructs containing the mutations indicated and live cell imaging performed
as described under ‘Methods’. This Figure is reproduced in colour in Molecular Membrane Biology online.
Basigin interaction with MCT1 491of experiments we confirmed these data using
MCT1 tagged with CFP on the N-terminus rather
than the C-terminus. Here FRET measurements
were also performed and these confirmed the lack of
interaction of R306E-MCT1-n-CFP with either
WT- or E218R-basigin-c-YFP. Mean 480:530nm
fluorescence emission ratio values (9 /SEM; n  /8)
of 1.299 /0.042 and 1.309 /0.084 were obtained
compared with 0.8279 /0.063 for the control FRET
pair (WT-MCT1-n-CFP with WT-basigin-c-YFP)
and 1.1439 /0.017 for the non-FRET pair (WT-
MCT1-n-CFP with WT-basigin-n-YFP).
Yet further confirmation for the inability of
R306E-MCT1 to be properly expressed at the
plasma membrane was obtained by measurement
of L-lactate transport into Xenopus oocytes using
BCECF fluorescence. Thus oocytes injected with
cRNA for R306E-MCT1 gave no lactate induced
pH change whether or not co-injected with cRNA
for E218R-basigin (data not shown). Nor did the
E218R-basigin inhibit expression of WT-MCT1 at
the plasma membrane (Figure 4B), implying that it
was not competing with endogenous basigin. This
was also confirmed with transport measurements
where Vmax values (9 /SE for 4 eggs) determined in
the absence and presence of E218R basigin were
0.429 /0.007 and 0.489 /0.009 fluorescence ratio
units per min respectively, with corresponding Km
values of 3.529 /0.23 and 2.739 /0.21 mM. These
data are summarized in Table I.
It has been suggested that Arg306 of MCT1 is likely
to form a charge-pair with Asp302 within TM 8
(Rahman et al. 1999). Although our data rule out a
simple charge-pair between R306 of MCT1 and
Glu218 of basigin, it remains a possibility that a more
complex charge interaction occurs within the mem-
brane that also involves Asp302. Thus we created the
double mutant D302R/R306E-MCT1 and looked at
its expression in Xenopus oocytes. In Figure 5 we
demonstrate by western blotting (panel A) and
immunofluorescence microscopy (panel B) that, un-
like the single R306E mutant, the double mutant was
translocated to the plasma membrane. As found for
WT-MCT1(Figure4B),co-injectionofeitherWT-or
E218R-basigin cRNA was without effect on D302R/
R306E MCT1 expression. However, we were unable
to demonstrate any lactate transport catalysed by the
expressed D302R/R306E MCT1, whether or not
cRNA for WT- or E218R-basigin was co-injected.
Thiswasconfirmedusingboththeradioactiveandthe
BCECF fluorescence transport assays (Table I).
These data suggest that a charge-pair between
Asp302 and Arg306 is essential for correct folding of
MCT1 and its translocation to the PM, and that
reversing the orientation of these groups is tolerated
for folding/translocation but not for catalytic activity.
Antibody
MCT1
Basigin
50 µ µm
Water WT MCT1 WT MCT1
WT basigin
R306E MCT1
E218R basigin
A
B
E218R basigin
WT MCT1
E218R basigin
R306E MCT1
Kidney
Water
WT MCT1
WT basigin
WT MCT1
R306E MCT1
WT basigin
R306E MCT1
43 kDa
Figure 4. R306E-MCT1 and E218R-basigin are not expressed at the plasma membrane of Xenopus oocytes. Oocytes were micro-injected
with the cRNA shown and after 72 hours some oocytes were used for immunoﬂuorescence microscopy with the antibody shown (panel A)
and others used for membrane preparation followed by SDS-PAGE (20 mg protein) and western blotting with anti-rat MCT1 antibody
(panel B). For the western blot, kidney plasma membranes were used as a positive control. The faint band in the water-injected controls
represents very slight sample contamination and is only visible because of the over-exposure of the blot to ensure any expressed MCTwas
detected. Further details are given under ‘Methods’. This Figure is reproduced in colour in Molecular Membrane Biology online.
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but is catalytically inactive
The data presented above suggest that the precise
geometry of Asp302 and Arg306 may be critical for
the catalytic mechanism of MCT1, and this was
further investigated by making the conservative
change of Arg306 to a lysine. Western blotting and
immunofluorescence microscopy confirmed that this
Kidney
Water
WT MCT1
D302R/R306E MCT1
E218R basigin
D302R/R306EMCT1
43 kDa
Secondary
D302R/R306E MCT1
D302R/R306E MCT1
WT basigin +
D302R/R306E MCT1 
WT basigin + 
D302R/R306E MCT1
E218R basigin + 
D302R/R306E MCT1 
E218R basigin + 
D302R/R306E MCT1
A
B
Anti-MCT1
Anti-basigin
50 m
Figure 5. D302R/R306E- MCT1 is expressed at the plasma membrane of Xenopus oocytes but is inactive. Details are as given for Figure 4.
Transport measurements are not shown because D302R/R306E-MCT1 failed to elicit any lactate transport whether or not WT- or E218R-
basigin cRNA was co-injected. This Figure is reproduced in colour in Molecular Membrane Biology online.
Table I. Summary of the expression and transport activity of wild-type and mutant MCT1 expressed in Xenopus laevis oocytes in the
presence and absence of WT- and mutant basigin. Where given, Vmax and Km values (9 /SE) were determined from the initial rates of
transport of L-lactate determined using BCECF ﬂuorescence as described under Methods. Four oocytes were used in each case and
L-lactate was added at 2.5, 5, 10, 20 and 40 mM. Data analysis was performed as described previously (Manning Fox et al. 2000). Where
no transport could be detected using BCECF conﬁrmation was made by determining the uptake of 0.5 mM L-[
14C]-lactate at 10 min as
described under Methods. Transport was indicated when uptake was signiﬁcantly greater than in water injected oocytes, but in no case in
which no BCECF response was detected was this observed. nd: not determined.
Transport measured using
BCECF
Plasma membrane expression determined
using:
Oocyte injection Detectable Km9 /SE (mM) Vmax9 /SE (^F.min
 1) Western blot Sections
WT-MCT1 Yes 3.529 /0.23 0.429 /0.007 Yes Yes
R306E-MCT1 No    No No
D302R/R306E-MCT1 No    Yes Yes
R306K-MCT1 No    Yes Yes
WT-MCT1  /WT-basigin Yes 2.949 /0.16 0.369 /0.005 Yes Yes
WT-MCT1  /E218Q-basigin Yes 2.739 /0.21 0.489 /0.009 Yes Yes
R306E-MCT1  /E218R-basigin No    No No
D302R/R306E-MCT1  /E218R-basigin No    Yes Yes
R306K-MCT1  /E218R-basigin No    Yes Yes
R86Q-MCT1 Yes 8.799 /1.5 0.429 /0.034 Yes nd
R86E-MCT1 Yes 6.489 /1.5 0.679 /0.050 Yes nd
Basigin interaction with MCT1 493mutant was translocated to the plasma membrane
(Figure 6), yet once again we were unable to
measure any lactate transport activity (data not
shown). Taken together, these data (summarized in
Table I) imply that not only is the correct orientation
of Asp302 and Arg306 essential for the catalytic
activity of MCT1 but that Arg306 plays a critical
role that cannot be substituted by lysine.
The role of other charged residues in transmembrane
helices of MCT1
Our structural predictions (Wilson et al. 2005)
based around the published crystal structures of
two members of the major facilitator superfamily,
the E. coli glycerol-3-phosphate transporter (GlpT)
and lactose permease (LacY) (Huang et al. 2003,
Abramson et al. 2003) suggested that Arg86, Arg196
and His337 might also be candidate residues for
forming a charge-pair with Glu218 in basigin. Of
these, Bro ¨er’s group have already mutated His337 to
glutamine and shown it to have no effect on either
MCT1 targeting to the plasma membrane or its
activity (Rahman et al. 1999). They also showed that
the same was true for Lys137,L y s 141,L y s 142 and
Arg143, although R143Q-MCT1 was inactive de-
spite being correctly targeted, (Rahman et al. 1999,
Galic et al. 2003). We have therefore focussed our
attention on Arg86 and Arg196, mutating both of
them to either glutamine glutamate. The R86Q-,
R86E-, R196Q- and R196E- mutants of MCT1
were all active when expressed in Xenopus oocytes,
and for R86Q-MCT1 and R86E-MCT1 the Km
values for L-lactate were determined and were not
significantly different from WT-MCT1 (Table I).
These data imply correct plasma membrane expres-
sion of the mutants in Xenopus oocytes. The same
was true in COS cells as shown in Figure 7 where we
used live cell imaging to demonstrate plasma mem-
brane expression of MCT1-c-CFP when co-ex-
pressed with basigin-c-YFP. In these experiments
we also co-expressed R86E-MCT1-c-CFP and
R196E-MCT1-c-CFP with E218R-basigin. In the
case of R196E-MCT1 no plasma membrane expres-
sion was observed as found previously for WT-
MCT1 (Figure 3). However, when either R86Q-
MCT1-c-CFP or R86E-MCT1-c-CFP was co-ex-
pressed with E218R-basigin-c-YFP both proteins
were expressed at the plasma membrane (Figure 7).
The interaction between R86Q-MCT1 and R86E-
Water
WT MCT1
R306K MCT1
E218R basigin
R306K MCT1
WT basigin
R306K MCT1
R306K MCT1
WT basigin + 
R306K MCT1 
WT basigin + 
R306K MCT1 
E218R basigin + 
R306K MCT1 
E218R basigin +
R306K MCT1 R306K MCT1
50 µ µm
Secondary Anti-basigin
A
B
Anti-MCT1
Figure 6. R306K-MCT1 is expressed at the plasma membrane of Xenopus oocytes but is inactive. Details are as given for Figure 4.
Transport measurements are not shown because R306K-MCT1 failed to elicit any lactate transport whether or not WT- or E218R-basigin
cRNA was co-injected. This Figure is reproduced in colour in Molecular Membrane Biology online.
494 C. Manoharan et al.MCT1 with E218R-basigin-c-YFP was studied
further using FRET and the data are presented in
Figure 8. Although not giving as much FRET
as WT-MCT1-c-CFP with WT-basigin-c-YFP,
the 480/530 fluorescence emission ratios for R86Q-
MCT1-c-CFP (0.989 /0.020) and R86E-MCT1-c-
CFP (0.979 /0.020) were significantly lower than
that observed for the non-FRET pair MCT1-c-CFP
with WT-basigin-n-YFP (1.189 /0.015) in the same
experiment. For R196E-MCT1-c-CFP expressed
with E218R-basigin-c-YFP, there was no plasma
membrane expression, and as predicted there was no
FRETobserved with the fluorescence emission ratio
being 1.119 /0.023.
For completion, we also mutated Lys38, Lys45 and
Arg404toglutamineorglutamate,butfoundthatallof
thesemutants ofMCT1wereexpressedattheplasma
membrane and showed catalytic activity. The results
are summarized in Supplementary data Table II.
Discussion
The data we present in this paper do not support our
earlier proposal that the transmembrane glutamate
(Glu218) of basigin must form a charge-pair with a
positively charged residue in a TM of MCT1 since
substituting this glutamate with the uncharged
glutamine does not prevent basigin fulfilling its
R86Q
R86E R196Q
R196E
R196E
WT
WT
R86E E218R
R86Q E218R
MCT1 Basigin
40 µ µm 40 µm
MCT1 Basigin
WT WT
WT
WT
E218R
Figure 7. Mutation of Arg86 or Arg196 to glutamine or glutamate does not prevent MCT1 from being correctly targeted to the plasma
membraneofCOScells.COScellswereco-transfectedwithMCT1-c-CFPandbasigin-c-YFPconstructscontainingthemutationsindicated
and live cell imaging performed as described under ‘Methods’. This Figure is reproduced in colour in Molecular Membrane Biology online.
Basigin interaction with MCT1 495role. However, our data are consistent with an
interaction between Glu218 in basigin and Arg86 in
TM3 of MCT1 as will be discussed further below.
Our data also confirm the importance of a charge-
pair between Asp302 and Arg306 in TM 8 of MCT1.
The validity of the model used to predict TM charges in
MCT1
There remains considerable uncertainty over the
precise registering of residues along the TM-heli-
ces in our revised model of the MCT1 structure
(Figure 1), as might be expected from the low
sequence identities between MCTs and the trans-
porter used as the structural template (E. coli
glycerol-3-phosphate transporter). Nevertheless,
our proposed structure exhibits several features
consistent with site-directed mutagenesis studies
performed here and elsewhere. First, Arg306 and
Asp302 in TM8 are properly aligned to form a
charged pair as suggested by the observation that
neither R306E nor D302R were expressed at the PM
whereas the double mutant was (Figures 2 & 3 and
Rahman et al. 1999). Second, F360C-MCT1 can
transport bulkier monocarboxylates than WT-
MCT1 (Kim-Garcia et al. 1994), suggesting that
Phe360 is in the substrate binding pocket. This
residue is close to Arg306 and Asp302 in our model.
Third, Galic et al. (2003) have identified another
likely charge-pair, between Arg143 (loop between
TM4 and TM5) and Glu369 (loop between TM10-
TM11), where again reversal of the charges allowed
expression but not activity. Their data suggested that
this charge-pair breaks during the translocation cycle
with a shift of TMs 8 and 10 and proton transfer
from Asp302 to Glu369. Flexibility of helix 5 is
required for this and our model allows it, although
in the conformation shown, Glu369 is well separated
from Arg143. However, it is at an appropriate
position in the TM domain to allow such an
interaction upon helix movement during the trans-
location cycle. We have previously shown a slight
increase in FRET between MCT1-c-CFP and
basigin-c-YFP upon substrate or inhibitor binding
that is consistent with such a conformational change
(Wilson et al. 2005). A feature of our new model
is that Arg196, that we originally placed in TM 6, is
now placed on the cytosolic surface of MCT1. This
is consistent with the data we present here that show
this residue to play no critical role in the interaction
ofMCT1 with basigin or its catalytic activity.
Glu218 in the transmembrane domain of basigin is not
essential for its function
As noted in the Introduction, the presence of a
charged residue such as glutamate in the transmem-
brane domain of a single pass protein is unusual
(Green 1991) and thus might be expected to play a
critical role in the function of basigin and embigin.
However, our data show that it can be mutated
to the uncharged glutamine and still interact with
MCT1 at the plasma in Xenopus oocytes (Figure 2)
and COS cells (Figure 3). In the former case, it was
also possible to confirm that E218Q-basigin sup-
ported MCT1 catalytic activity (Figure 2). However,
when Glu218 was mutated to the positively charged
arginine, the protein was not properly targeted to the
plasma membrane in either COS cells (Figure 3) or
Xenopus oocytes (Figure 4). It was previously
postulated that Glu218 of basigin might charge-pair
with a positively charged residue in a transmembrane
helix of MCT1, for which the obvious candidate is
Arg306 (Wilson et al. 2002). This now seems unlikely
0.6
0.7
0.8
0.9
1.0
1.1
1.2
WT
WT Basigin
Basigin-
n-YFP
MCT1-c-CFP
4
8
0
/
5
3
0
 
f
l
u
o
r
e
s
c
e
n
c
e
 
e
m
i
s
s
i
o
n
 
r
a
t
i
o
WT
WT
R86E
E218Q
R86Q
WT
R86E
WT
R86Q
E218R E218R
Basigin-c-YFP
WT
E218R
WT
25 23 17 12 10 10 9 9
R196E
E218R
12
Figure 8. FRET measurements suggest that mutation of Arg86 perturbs the interaction of MCT1 with basigin. COS cells were co-
transfected with MCT1-c-CFP and basigin-c-YFP constructs containing the mutations indicated and live cell imaging with determination
of FRET performed as described under ‘Methods’. Data are presented as means9 /SEM for the number of observations shown.
496 C. Manoharan et al.since E218R-basigin could not be rescued by co-
expressing with R306E MCT1 (Figures 3 and 4), yet
it would be predicted that any charge-pair would be
retained under these conditions, although with
reverse polarity.
Two other strong candidates for positively charged
residues in TM domains of MCT1 that might
interact with Glu218 of basigin, identified from our
structural model of MCT1 (Figure 1), are Arg86 and
His337. However, Rahman et al. (1999) have shown
that H337Q-MCT1 is expressed in active form at
the plasma membrane ruling out such a role for this
residue. Our own data (Figure 7 and Supplementary
data Table II) allow us to draw the same conclusion
for Arg86, since swapping the charge from positive to
neutral (glutamine) or negative (glutamate) did not
prevent the expression of active MCT1 at the plasma
membrane. Overall, our data appear to rule out an
essential charge-pair between Glu218 of basigin and a
positively charged TM residue of MCT1 and would
be compatible with Glu218 being protonated and
thus uncharged within the membrane.
Confirmation that Arg306 forms a charge-pair with
Asp302 in TM 8 of MCT1
The proposal that Arg306 in TM 8 of MCT1 forms a
charge-pair with Asp302 within the same TM as
proposed by (Rahman et al. 1999) is supported by
our model and here we have confirmed it experi-
mentally. Thus when either residue was mutated on
its own, the protein was poorly expressed at the
plasma membrane (Figures 2 4), whereas the dou-
ble mutant, with the charges swapped, did reach the
membrane (Figure 5). However, the double mutant
was found to be catalytically inactive, implying that
the geometry of the interaction may be critical for
correct function. Interestingly, Galic et al. (2003)
have shown that Arg143 and Glu369 are also likely to
form a charge-pair and here too, reversal of the
charges allows correct folding and membrane trans-
location but not catalytic activity. Further evidence
for the critical geometry surrounding the charge-pair
of Asp302 with Arg306 if MCT1 is to be catalytically
active is the observation of Rahman et al. (1999) that
Asp302 cannot be replaced by the conservative
change to a glutamate. Furthermore, our own data
reveal that although the conservative replacement of
Arg306 with lysine allows for expression at the plasma
membrane (Figure 6), the protein is catalytically
inactive (Supplementary data Table II). This is a
similar situation to that found in lactate dehydro-
genase where arginine is critical for substrate binding
(Hart et al. 1987) and like lactate dehydrogenase,
MCT1 is inhibited by the arginine-specific agent,
phenylglyoxal (Donovan & Jennings 1986, Poole &
Halestrap 1993).
Where does basigin bind to MCT1?
Although our data argue against an essential inter-
action of Glu218 of basigin with a charged residue in
a TM of MCT1, we do provide some evidence that
Arg86 in TM3 of MCT1 may be in close proximity
to Glu218 of basigin. This is implied by the data of
Figure 7 showing that E218R-basigin can associate
with R86E-MCT1 and R86Q-MCT1 at the plasma
membrane, but not with WT-MCT1. This can be
explained if TM3 of MCT1 lies alongside the TM of
basigin, which would fit well with our structural
model for MCT1 that places TM3 on the lipid-
facing surface of MCT1. Arg86 is in the middle of
TM3 where it could readily form a charge pair
within the membrane with Glu218 in the middle of
the TM of basigin. The same would be the case
when the charges are swapped in cells expressing
E218R-basigin with R86E-MCT1. However, when
WT-MCT1 (with Arg at position 86) is expressed
with E218R-basigin, association of the two proteins
will be prevented by the presence of the two positive
charges in close proximity in the membrane. Other
combinations of the two residues that do not allow
an appropriate charge-pair are tolerated as shown by
co-expression of the proteins at the plasma mem-
brane and their FRET, albeit less well than for the
WT proteins (Figure 8). Under these circumstances
the presence of an unpaired arginine or glutamate
residue in the membrane may be enabled either by
stabilization of the unionized residues through
hydrogen bonding or through local distortion of
the helical structure placing the tip of the charged
residue outside of the hydrophobic region of the
bilayer.
Additional evidence for the TM of basigin inter-
acting with TM3 of the MCT comes from our earlier
studies in which we demonstrated that substitution
of cysteine with alanine or serine residues in TMs 3
and 6 of MCT4 increased its sensitivity to inhibi-
tion by p-chloromercuribenzene sulphonate (Wilson
et al. 2005). This organomercurial reagent also
prevented co-immunoprecipitation of MCT4 and
MCT1 with basigin, consistent with the substitution
of theses cysteine residues perturbing the interaction
between basigin and the MCT. Our model suggests
that TM6 lies adjacent to TM3 on the lipid-facing
surface of MCT1 and thus it is possible that the TM
helix of basigin lies between TMs 3 and 6 of MCT1.
Further studies will be required to confirm these
proposals.
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